Cysteine News and Research

RSS

Study uncovers novel treatment for chromophobe renal cell carcinoma

Chromophobe renal cell carcinoma (ChRCC) is a rare form of kidney cancer for which there are currently no proven treatments for metastatic or unresectable disease.

20 Jun 2022

The role of ARF6 in SARS-CoV-2 endocytosis and infection

Researchers assessed the role of adenoside diphosphate (ADP)-ribosylation factor 6 (ARF6) in SARS-CoV-2 infection.

14 Jun 2022

SARS-CoV-2 is a generalist virus, infecting and evolving in numerous mammals and humans

In a recent article published in the bioRxiv* preprint server, researchers illustrated zooanthroponotic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission and viral mutations specific to hosts.

8 Jun 2022

De novo-designed mini-protein against SARS-CoV-2

Researchers characterized truncated forms of LCB1, a de novo-designed mini-protein, against SARS-CoV-2.

7 Jun 2022

The link between androgens and COVID-19

A new paper examines the association between androgens and COVID-19, as revealed by the research carried out on this topic throughout the pandemic.

20 May 2022

Camelid IFNs could play important role in combating emerging zoonotic pathogens

In a recent study published in the Developmental & Comparative Immunology journal, the discovery of a novel form of mammalian interferon-Beta (IFN-β) with four cysteine residues from the dromedary camel and the five remaining members of the mammalian suborder Tylopoda is described.

17 May 2022

Marine bioactive compounds against SARS-CoV-2

A new review paper published in the journal Environmental Science and Pollution Research aimed to determine the possibilities of using biologically active compounds derived from various chemical classes of marine organisms against SARS-CoV-2 infection at various stages of the life cycle of the virus.

6 May 2022

SARS-CoV-2 Mpro inhibitors built on rattlesnake venom scaffold

A new study describes the development of new molecules with inhibitory activity against the SARS-CoV-2 viral main protease (Mpro) enzyme, based on rattlesnake venom.

29 Apr 2022

Study reports an orally available SARS-CoV-2 Mpro inhibitor with potent in vivo antiviral activity

Researchers examined the efficiency of the main protease (Mpro) inhibitor against SARS-CoV-2.

29 Apr 2022

Researchers discover molecular mechanisms underlying extreme need for amino acids in neuroblastoma

Certain childhood tumors have an extreme need for amino acids. Scientists at the Hopp Children's Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ), the University of Heidelberg, and HI-STEM gGmbH have now discovered the molecular mechanisms underlying this and how the cancer cells could be turned off.

28 Apr 2022

The potency of halicin against the main protease of SARS-CoV-2

A new paper published in Current Research in Chemical Biology discusses the potential of a molecule called halicin against SARS-CoV-2.

26 Apr 2022

Quercetin and other plant flavonols show anti-SARS-CoV-2 activity

A new study discusses the potential of certain plant compounds to block SARS-CoV-2 replication within host cells.

24 Apr 2022

Addition of left-handed chiral gold nanoparticles can enhance vaccine efficacy by more than 25%

Vaccines can be made over 25% more effective by adding left-handed chiral gold nanoparticles as adjuvants, according to a study by an international collaboration in which Brazilian researchers took part. An article reporting the results is published in Nature.

18 Apr 2022

COVID-19 may affect a group of biochemical reactions called one-carbon metabolism

A new study addresses the relationship between SARS-CoV-2 to the metabolism of one-carbon molecules in the host, suggesting new therapeutic pathways.

13 Apr 2022

S-Nitrosylation of ACE2 inhibits binding of SARS-CoV-2 spike protein

In a recent study posted to the bioRxiv* preprint server, researchers developed aminoadamantane nitrates compounds that inhibit the ion channels formed by the envelope (E) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and enable targeted drug delivery of nitric oxide (NO)-related group for S-nitrosylation of host angiotensin-converting enzyme 2 (ACE2), which would inhibit ACE2 binding with the viral spike (S) protein and thereby inhibit viral replication in the host.

11 Apr 2022

Framework for genomic surveillance of SARS-CoV-2 Mpro evolution

A recent study posted to the bioRxiv* preprint server investigated the active genetic evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro), its emerging mutations, and the existence of antiviral resistance against Mpro inhibitors like paxlovid.

5 Apr 2022